Curcumin attenuates hyperglycemia-driven EGF-induced invasive and migratory abilities of pancreatic cancer via suppression of the ERK and AKT pathways
- PMID: 30542713
- DOI: 10.3892/or.2018.6833
Curcumin attenuates hyperglycemia-driven EGF-induced invasive and migratory abilities of pancreatic cancer via suppression of the ERK and AKT pathways
Abstract
The relationship between diabetes mellitus and pancreatic cancer is complex. Diabetes has been postulated to be both an independent risk factor and a consequence of pancreatic cancer. Our previous study confirmed that curcumin plays a vital role in inhibiting the epithelial-mesenchymal transition of pancreatic cancer cells. However, whether curcumin attenuates hyperglycemia-induced cancer invasive and migratory abilities and the underlying mechanisms are not yet well understood. As high glucose is able to induce the expression of epidermal growth factor (EGF), which is intimately related with tumor progression, the aim of this study was to evaluate whether curcumin could influence the high glucose-induced EGF/EGFR pathway and the biological activity of pancreatic cancer cells. Human pancreatic cancer BxPC-3 cells were exposed to high glucose or EGF, with or without curcumin, LY 294002 (an Akt inhibitor) or PD 98059 (an ERK inhibitor). MTT, Transwell invasion and wound healing assays were used to detect the proliferation, invasion and migration potential of cancer cells. The activation of p-EGFR, p-ERK and p-Akt was determined by western blot analysis. The expression levels of uPA and E-cadherin were examined using qRT-PCR and western blot analysis. The results showed that high glucose could not only promote the proliferation, invasion and migration of pancreatic cancer cells, but also induce the expression of EGF and activation of EGFR, ERK and Akt. These effects of high glucose were counter-balanced by curcumin. EGF-induced proliferative, invasive and migratory abilities of BxPC-3 cells were abrogated by curcumin, LY 294002 and PD 98059. In addition, EGF-modulated activation of EGFR, ERK and Akt, as well as the expression of uPA and E-cadherin were inhibited by curcumin. Taken together, the present study indicates that curcumin suppresses hyperglycemia-driven EGF-induced invasion and migration of pancreatic cancer cells by inhibiting the EGF/EGFR signaling pathway and its downstream signaling molecules including ERK and Akt. Curcumin is a potential anticancer agent for pancreatic cancer.
Similar articles
-
Resveratrol inhibits hyperglycemia-driven ROS-induced invasion and migration of pancreatic cancer cells via suppression of the ERK and p38 MAPK signaling pathways.Int J Oncol. 2016 Aug;49(2):735-43. doi: 10.3892/ijo.2016.3559. Epub 2016 Jun 3. Int J Oncol. 2016. PMID: 27278736
-
Curcumin inhibits H2O2-induced invasion and migration of human pancreatic cancer via suppression of the ERK/NF-κB pathway.Oncol Rep. 2016 Oct;36(4):2245-51. doi: 10.3892/or.2016.5044. Epub 2016 Aug 25. Oncol Rep. 2016. PMID: 27572503
-
Curcumin inhibits hypoxia-induced epithelial‑mesenchymal transition in pancreatic cancer cells via suppression of the hedgehog signaling pathway.Oncol Rep. 2016 Jun;35(6):3728-34. doi: 10.3892/or.2016.4709. Epub 2016 Mar 28. Oncol Rep. 2016. PMID: 27035865
-
Phytosomal Curcumin Elicits Anti-tumor Properties Through Suppression of Angiogenesis, Cell Proliferation and Induction of Oxidative Stress in Colorectal Cancer.Curr Pharm Des. 2018;24(39):4626-4638. doi: 10.2174/1381612825666190110145151. Curr Pharm Des. 2018. PMID: 30636578 Review.
-
Targeting the Akt signaling pathway: Exploiting curcumin's anticancer potential.Pathol Res Pract. 2024 Sep;261:155479. doi: 10.1016/j.prp.2024.155479. Epub 2024 Jul 20. Pathol Res Pract. 2024. PMID: 39068859 Review.
Cited by
-
Curcumin inhibited the growth and invasion of human monocytic leukaemia SHI-1 cells in vivo by altering MAPK and MMP signalling.Pharm Biol. 2020 Dec;58(1):25-34. doi: 10.1080/13880209.2019.1701042. Pharm Biol. 2020. PMID: 31854220 Free PMC article.
-
High glucose: an emerging association between diabetes mellitus and cancer progression.J Mol Med (Berl). 2021 Sep;99(9):1175-1193. doi: 10.1007/s00109-021-02096-w. Epub 2021 May 26. J Mol Med (Berl). 2021. PMID: 34036430 Review.
-
Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer.Front Pharmacol. 2021 Nov 15;12:772510. doi: 10.3389/fphar.2021.772510. eCollection 2021. Front Pharmacol. 2021. PMID: 34867402 Free PMC article. Review.
-
Curcumin targets miR-134-5p to suppress the progression of colorectal cancer through regulating the CDCA3/CDK1 pathway.Naunyn Schmiedebergs Arch Pharmacol. 2024 Jan;397(1):109-122. doi: 10.1007/s00210-023-02584-5. Epub 2023 Jun 27. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 37368030
-
Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer.Front Chem. 2020 Oct 15;8:829. doi: 10.3389/fchem.2020.00829. eCollection 2020. Front Chem. 2020. PMID: 33195038 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous